Seattle Genetics is a company working on revolutionizing cancer therapy. At the head of that revolution is co-founder and CEO Dr. Clay Siegall.
For the past 17 years, Seattle Genetics, under Dr. Siegall’s leadership, has worked to create breakthrough concepts in cancer therapies through the research and development of antibody-drug conjugates, or ADC’s.
ADC’s are a targeted therapy in the treatment of cancer, inhibiting the growth of cancerous cells without damaging the body’s healthy cells like traditional chemotherapy. Seattle Genetics dedication and tireless research continue to innovate and show encouraging progress in antibody-drug conjugates.
Through Dr. Siegall’s guidance and direction, Seattle Genetics technological advances have contributed to the development of more than 20 ADC’s. Siegall, a graduate of the University of Maryland, and George Washington University is committed to the company’s growth and continued research. Thanks to his vigorous efforts, he has managed to secure more than 675 million dollars through private and public funding. International partnerships have also contributed to the company’s growth and assets.
Dr. Siegall is proud of the research and technologies Seattle Genetics has created in its crusade against cancer. The company’s ADCETRIS, a new class of ADC’s, has shown positive results in more than 15,000 lymphoma patients in the U.S and abroad. About half of the patients that undergo autologous stem cell transplant face the threat of relapsing. Seattle Genetics is working to develop new therapies that would reduce the risk and increase the patient’s chances of a successful recovery.
With their dedication, continued research, and fundraising, Dr. Siegall, and Seattle Genetics will continue to lead the way in cancer treatment innovation.
Read about Clay: